Ballentine Partners LLC Acquires New Position in Amedisys, Inc. (NASDAQ:AMED)

Ballentine Partners LLC bought a new position in shares of Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, HoldingsChannel.com reports. The firm bought 3,684 shares of the health services provider’s stock, valued at approximately $334,000.

Other large investors have also added to or reduced their stakes in the company. Westchester Capital Management LLC boosted its stake in shares of Amedisys by 9.5% in the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock worth $107,976,000 after acquiring an additional 97,476 shares during the period. Geode Capital Management LLC boosted its stake in Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after purchasing an additional 7,071 shares during the period. Dimensional Fund Advisors LP boosted its stake in Amedisys by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider’s stock worth $47,202,000 after purchasing an additional 19,660 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after buying an additional 9,004 shares in the last quarter. Finally, Polar Asset Management Partners Inc. bought a new stake in shares of Amedisys during the third quarter valued at approximately $28,953,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $92.80 on Friday. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 36.83, a P/E/G ratio of 1.83 and a beta of 0.72. The firm has a fifty day moving average price of $89.17 and a 200 day moving average price of $94.20. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $587.67 million for the quarter, compared to the consensus estimate of $586.75 million. During the same period last year, the company earned $0.98 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, sell-side analysts expect that Amedisys, Inc. will post 4.43 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.